Join our daily newsletter At The Bell to receive exclusive market insights
- Little Green Pharma (LGP) signs a deal with Frankfurt licenced pharmaceutical wholesaler Ilios Santé for the supply of medicinal cannabis products into Germany
- Under the agreement, Ilios Santé must purchase minimum orders of a high-THC white-label medicinal cannabis flower product being developed by LGP
- The contract will last for two years and will have a minimum value of $2 million
- The company believes the agreement shows its continued success of the extensive genetics program which has resulted in “a world-class” bank of cannabis cultivars
- Shares in Little Green Pharma close in the day in the grey, trading at 32 cents
Little Green Pharma (LGP) has signed a deal with Frankfurt licenced pharmaceutical wholesaler Ilios Santé for the supply of medicinal cannabis products into Germany.
Under the agreement, Ilios Santé must purchase minimum orders of 20 kilograms per shipment of a high-THC white-label medicinal cannabis flower product being developed by THC.
The 20-kilogram purchase will take place after the first six months, with a projected 80 per cent of minimum quantities falling in the second year.
The contract will last for two years and will have a minimum value of $2 million.
Commenting on the agreement, Little Green Pharma CEO Fleta Solomon said the partnership strengthens the company’s share of the medicinal cannabis product market in Germany as a start.
“[This partnership also] strategically partners us with The Bloomwell Group, a European leader in medical cannabis groups operating along the entire value chain,” she said.
“We look forward to collaborating with Ilios Santé to help service our rapidly growing number of medicinal cannabis patients in Germany.”
The company believes the agreement shows its continued success of the extensive genetics program which has resulted in “a world-class” bank of cannabis cultivars.
Further, the agreement joins Little Green Pharma’s portfolio of rapidly expanding suite of high-value supply agreements in Europe and consolidates its “growing industry reputation” as one of the world’s leading pure-play medicinal cannabis suppliers.
Shares in Little Green Pharma closed in the grey, trading at 32 cents.
